COMMUNIQUÉS West-GlobeNewswire

Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
05/11/2018
BOSTON and LONDON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases [...]
Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates
05/11/2018
U.S. Galafold ® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch 3Q18 Global Galafold Net Product Sales of $20.6M Driven by Continued [...]
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
05/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual Scientific Meeting of the [...]
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on November 12
05/11/2018
REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and [...]
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
05/11/2018
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10 million paid upon [...]
Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility
05/11/2018
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, will officially cut the ribbon on its San Diego based research and development facility on Monday [...]
Dova Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic Immune Thrombocytopenia (ITP)
05/11/2018
DURHAM, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a [...]
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
05/11/2018
- Focusing Resources on Uveitis Program; NDA Filing Expected Fourth Quarter 2018 - - Company to Host Conference Call at 8:30 a.m. ET to Review the 8-Week Topline Data - ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE [...]
AnaptysBio to Participate in Upcoming Investor Conferences
05/11/2018
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, [...]
Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019
05/11/2018
BURLINGTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a product-specific J code for ZILRETTA ( [...]
Alpha Pro Tech, Ltd. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2018
05/11/2018
Revenue for the third quarter of 2018 increased modestly to $12.1 million, compared to $12.0 million for the third quarter of 2017. Revenue for the nine months ended September 30, 2018 increased 4.6% to $35.7 million, [...]
Invitation to investor meeting on November 8, 2018
05/11/2018
In connection with the release of BioPorto’s interim report covering the first nine months of 2018, BioPorto will hold an investor meeting on November 8, 2018 at. 3 pm. at BioPorto’s address Tuborg Havnevej 15, st., [...]
Quotient Limited Reports Positive MosaiQ Audit Results and Instrument CE Mark with Second Quarter Fiscal 2019 Financial Results
05/11/2018
Positive MosaiQ manufacturing facility audit results MosaiQ instrument CE mark self certification complete Year to date reagent product revenues growing at 16% JERSEY, Channel Islands, Nov. 05, 2018 (GLOBE NEWSWIRE) -- [...]
Capital Senior Living Corporation to Present at the Stephens NY Investment Conference on Wednesday, November 7, 2018
05/11/2018
DALLAS, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Capital Senior Living Corporation (the “Company”) (NYSE:CSU), one of the country’s largest operators of senior housing communities, today announced that management will make a [...]
Arrayit Corporation Announces Brands Expansion of Proprietary Finger Stick Allergy Testing
05/11/2018
Sunnyvale, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, announces expansion of its proprietary finger stick microarray allergy testing platform [...]
Enzymatica AB: Bulletin from Extraordinary General Meeting in Enzymatica AB (publ)
05/11/2018
Press release 5 November, 2018 Bulletin from Extraordinary General Meeting in Enzymatica AB (publ) Today's Extraordinary General Meeting in Enzymatica AB (publ) resolved to approve the Board of Directors' resolution on [...]
William Demant Holding A/S: Financial calendar 2019
05/11/2018
Company announcement no 2018-10 5 November 2018 Financial calendar 2019 The following dates for publication of the Company’s Annual Report, Interim Report and Interim Management Statements as well as holding of the [...]
Biohit Oyj B-shares Subscribed with Stock Options I 2013
05/11/2018
Biohit Oyj Stock Exchange Release November 5, 2018 at 09.30 a.m. (EEST) A total number of 52,709 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 between 5 June 2018 and 8 September 2018. These [...]
Exalenz to Present Positive Clinical Data for the Breath ID® 13C-Methacetin Breath Test System at the Liver Meeting® 2018
05/11/2018
MODI’IN, Israel and MANASQUAN, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of [...]

Pages